Hepatitis Vaccine Market Size, Industry Share and Global Forecast 2025 - 2033
Description
The Global Hepatitis Vaccine Market Size accounted for USD 6.87 Billion in 2024 and is estimated to achieve a market size of USD 11.03 Billion by 2032 growing at a CAGR of 5.5% from 2025 to 2033.
The global hepatitis vaccine market is a rapidly growing sector driven by the increasing global burden of hepatitis infections, rising awareness of the importance of vaccination, and advancements in vaccine development. Hepatitis is a major public health issue worldwide, with viral hepatitis being responsible for millions of deaths annually due to liver disease, cirrhosis, and liver cancer. The World Health Organization (WHO) estimates that approximately 325 million people worldwide are living with chronic hepatitis B or C, and these infections remain a leading cause of morbidity and mortality. Hepatitis vaccines play a crucial role in preventing these infections, and their widespread use has been a cornerstone of global efforts to reduce the prevalence of viral hepatitis. The hepatitis vaccine market is expected to experience significant growth due to the increasing demand for vaccination programs, growing government and healthcare sector initiatives, and innovations in vaccine development aimed at expanding coverage and improving efficacy.
Hepatitis Vaccine Market Segmentation
The worldwide market for hepatitis vaccine is split based on indication, vaccine type, distribution channel, and geography.
Hepatitis Vaccine Indication
Hepatitis A
Hepatitis B
Hepatitis Vaccine Type
Recombinant Vaccine
Inactivated Vaccine
Hepatitis Vaccine Distribution Channel
Hospitals
Retail Pharmacy
Online Pharmacy
Hepatitis Vaccine Market Regional Outlook
North America
U.S.
Canada
Europe
U.K.
Germany
France
Spain
Rest of Europe
Asia-Pacific
India
Japan
China
Australia
South Korea
Rest of Asia-Pacific
Latin America
Brazil
Mexico
Rest of LATAM
The Middle East & Africa
South Africa
GCC Countries
Rest of the Middle East & Africa (ME&A)
Hepatitis Vaccine Market Players
Some of the top hepatitis vaccine companies offered in our report include GSK plc, DYNAVAX TECHNOLOGIES, VBI Vaccines Inc., Sanofi, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Sinovac Biotech Ltd., Biokangtai, Pfizer Inc., and Gilead Sciences, Inc.
How Acumen Research and Consulting Reserch Study of helps clients in their decision making:
Creating strategies for new product development
Supporting & Adjust Investment/business decisions
Benchmark and judge own competitiveness
Aiding in the business planning process
Serving as a credible, independent check on company internal forecasts
Supporting acquisition strategies
The global hepatitis vaccine market is a rapidly growing sector driven by the increasing global burden of hepatitis infections, rising awareness of the importance of vaccination, and advancements in vaccine development. Hepatitis is a major public health issue worldwide, with viral hepatitis being responsible for millions of deaths annually due to liver disease, cirrhosis, and liver cancer. The World Health Organization (WHO) estimates that approximately 325 million people worldwide are living with chronic hepatitis B or C, and these infections remain a leading cause of morbidity and mortality. Hepatitis vaccines play a crucial role in preventing these infections, and their widespread use has been a cornerstone of global efforts to reduce the prevalence of viral hepatitis. The hepatitis vaccine market is expected to experience significant growth due to the increasing demand for vaccination programs, growing government and healthcare sector initiatives, and innovations in vaccine development aimed at expanding coverage and improving efficacy.
Hepatitis Vaccine Market Segmentation
The worldwide market for hepatitis vaccine is split based on indication, vaccine type, distribution channel, and geography.
Hepatitis Vaccine Indication
Hepatitis A
Hepatitis B
Hepatitis Vaccine Type
Recombinant Vaccine
Inactivated Vaccine
Hepatitis Vaccine Distribution Channel
Hospitals
Retail Pharmacy
Online Pharmacy
Hepatitis Vaccine Market Regional Outlook
North America
U.S.
Canada
Europe
U.K.
Germany
France
Spain
Rest of Europe
Asia-Pacific
India
Japan
China
Australia
South Korea
Rest of Asia-Pacific
Latin America
Brazil
Mexico
Rest of LATAM
The Middle East & Africa
South Africa
GCC Countries
Rest of the Middle East & Africa (ME&A)
Hepatitis Vaccine Market Players
Some of the top hepatitis vaccine companies offered in our report include GSK plc, DYNAVAX TECHNOLOGIES, VBI Vaccines Inc., Sanofi, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Sinovac Biotech Ltd., Biokangtai, Pfizer Inc., and Gilead Sciences, Inc.
How Acumen Research and Consulting Reserch Study of helps clients in their decision making:
Creating strategies for new product development
Supporting & Adjust Investment/business decisions
Benchmark and judge own competitiveness
Aiding in the business planning process
Serving as a credible, independent check on company internal forecasts
Supporting acquisition strategies
Table of Contents
250 Pages
- CHAPTER 1 Industry Overview of Hepatitis Vaccine Market
- 1.1 Definition and Scope
- 1.2 Summary
- CHAPTER 2 Research Approach
- 2.1 Methodology
- 2.2 Data Source
- CHAPTER 3 Market Dynamics And Competition Analysis
- 3.1 Market Drivers
- 3.2 Restraints and Challenges
- 3.3 Growth Opportunities
- 3.4 Porter’s Five Forces Analysis
- 3.4.1 Bargaining Power of Suppliers
- 3.4.2 Bargaining Power of Buyers
- 3.4.3 Threat of Substitute
- 3.4.4 Threat of New Entrants
- 3.4.5 Degree of Competition
- 3.5 Market Concentration Ratio and Market Maturity Analysis of Hepatitis Vaccine Market
- 3.5.1 Go To Market Strategy
- 3.5.1.1 Introduction
- 3.5.1.2 Growth
- 3.5.1.3 Maturity
- 3.5.1.4 Saturation
- 3.5.1.5 Possible Development
- 3.6 Technological Roadmap for Hepatitis Vaccine Market
- 3.7 Value Chain Analysis
- 3.7.1 List of Key Manufacturers
- 3.7.2 List of Customers
- 3.7.3 Level of Integration
- 3.8 Cost Structure Analysis
- 3.8.1 Price Trend of Key Raw Materials
- 3.8.2 Raw Material Suppliers
- 3.8.3 Proportion of Manufacturing Cost Structure
- 3.8.3.1 Raw Material
- 3.8.3.2 Labor Cost
- 3.8.3.3 Manufacturing Expense
- 3.9 Regulatory Compliance
- 3.10 Competitive Landscape, 2024
- 3.10.1 Player Positioning Analysis
- 3.10.2 Key Strategies Adopted By Leading Players
- CHAPTER 4 Manufacturing Plant Analysis
- 4.1 Manufacturing Plant Location and Establish Date of Major Manufacturers in 2024
- 4.2 R&D Status of Major Manufacturers in 2024
- CHAPTER 5 Hepatitis Vaccine Market By Indication
- 5.1 Introduction
- 5.2 Hepatitis Vaccine Revenue By Indication
- 5.2.1 Hepatitis Vaccine Revenue (USD Million) and Forecast, By Indication, 2021-2033
- 5.2.2 Hepatitis A
- 5.2.2.1 Hepatitis A Market Revenue (USD Million) and Growth Rate (%), 2021-2033
- 5.2.3 Hepatitis B
- 5.2.3.1 Hepatitis B Market Revenue (USD Million) and Growth Rate (%), 2021-2033
- CHAPTER 6 Hepatitis Vaccine Market By Vaccine Type
- 6.1 Introduction
- 6.2 Hepatitis Vaccine Revenue By Vaccine Type
- 6.2.1 Hepatitis Vaccine Revenue (USD Million) and Forecast, By Vaccine Type, 2021-2033
- 6.2.2 Recombinant Vaccine
- 6.2.2.1 Recombinant Vaccine Market Revenue (USD Million) and Growth Rate (%), 2021-2033
- 6.2.3 Inactivated Vaccine
- 6.2.3.1 Inactivated Vaccine Market Revenue (USD Million) and Growth Rate (%), 2021-2033
- CHAPTER 7 Hepatitis Vaccine Market By Distribution Channel
- 7.1 Introduction
- 7.2 Hepatitis Vaccine Revenue By Distribution Channel
- 7.2.1 Hepatitis Vaccine Revenue (USD Million) and Forecast, By Distribution Channel, 2021-2033
- 7.2.2 Hospitals
- 7.2.2.1 Hospitals Market Revenue (USD Million) and Growth Rate (%), 2021-2033
- 7.2.3 Retail Pharmacy
- 7.2.3.1 Retail Pharmacy Market Revenue (USD Million) and Growth Rate (%), 2021-2033
- 7.2.4 Online Pharmacy
- 7.2.4.1 Online Pharmacy Market Revenue (USD Million) and Growth Rate (%), 2021-2033
- CHAPTER 8 North America Hepatitis Vaccine Market By Country
- 8.1 North America Hepatitis Vaccine Market Overview
- 8.2 U.S.
- 8.2.1 U.S. Hepatitis Vaccine Revenue (USD Million) and Forecast By Indication, 2021-2033
- 8.2.2 U.S. Hepatitis Vaccine Revenue (USD Million) and Forecast By Vaccine Type, 2021-2033
- 8.2.3 U.S. Hepatitis Vaccine Revenue (USD Million) and Forecast By Distribution Channel, 2021-2033
- 8.3 Canada
- 8.3.1 Canada Hepatitis Vaccine Revenue (USD Million) and Forecast By Indication, 2021-2033
- 8.3.2 Canada Hepatitis Vaccine Revenue (USD Million) and Forecast By Vaccine Type, 2021-2033
- 8.3.3 Canada Hepatitis Vaccine Revenue (USD Million) and Forecast By Distribution Channel, 2021-2033
- 8.4 North America PEST Analysis
- CHAPTER 9 Europe Hepatitis Vaccine Market By Country
- 9.1 Europe Hepatitis Vaccine Market Overview
- 9.2 U.K.
- 9.2.1 U.K. Hepatitis Vaccine Revenue (USD Million) and Forecast By Indication, 2021-2033
- 9.2.2 U.K. Hepatitis Vaccine Revenue (USD Million) and Forecast By Vaccine Type, 2021-2033
- 9.2.3 U.K. Hepatitis Vaccine Revenue (USD Million) and Forecast By Distribution Channel, 2021-2033
- 9.3 Germany
- 9.3.1 Germany Hepatitis Vaccine Revenue (USD Million) and Forecast By Indication, 2021-2033
- 9.3.2 Germany Hepatitis Vaccine Revenue (USD Million) and Forecast By Vaccine Type, 2021-2033
- 9.3.3 Germany Hepatitis Vaccine Revenue (USD Million) and Forecast By Distribution Channel, 2021-2033
- 9.4 France
- 9.4.1 France Hepatitis Vaccine Revenue (USD Million) and Forecast By Indication, 2021-2033
- 9.4.2 France Hepatitis Vaccine Revenue (USD Million) and Forecast By Vaccine Type, 2021-2033
- 9.4.3 France Hepatitis Vaccine Revenue (USD Million) and Forecast By Distribution Channel, 2021-2033
- 9.5 Spain
- 9.5.1 Spain Hepatitis Vaccine Revenue (USD Million) and Forecast By Indication, 2021-2033
- 9.5.2 Spain Hepatitis Vaccine Revenue (USD Million) and Forecast By Vaccine Type, 2021-2033
- 9.5.3 Spain Hepatitis Vaccine Revenue (USD Million) and Forecast By Distribution Channel, 2021-2033
- 9.6 Rest of Europe
- 9.6.1 Rest of Europe Hepatitis Vaccine Revenue (USD Million) and Forecast By Indication, 2021-2033
- 9.6.2 Rest of Europe Hepatitis Vaccine Revenue (USD Million) and Forecast By Vaccine Type, 2021-2033
- 9.6.3 Rest of Europe Hepatitis Vaccine Revenue (USD Million) and Forecast By Distribution Channel, 2021-2033
- 9.7 Europe PEST Analysis
- CHAPTER 10 Asia Pacific Hepatitis Vaccine Market By Country
- 10.1 Asia Pacific Hepatitis Vaccine Market Overview
- 10.2 China
- 10.2.1 China Hepatitis Vaccine Revenue (USD Million) and Forecast By Indication, 2021-2033
- 10.2.2 China Hepatitis Vaccine Revenue (USD Million) and Forecast By Vaccine Type, 2021-2033
- 10.2.3 China Hepatitis Vaccine Revenue (USD Million) and Forecast By Distribution Channel, 2021-2033
- 10.3 Japan
- 10.3.1 Japan Hepatitis Vaccine Revenue (USD Million) and Forecast By Indication, 2021-2033
- 10.3.2 Japan Hepatitis Vaccine Revenue (USD Million) and Forecast By Vaccine Type, 2021-2033
- 10.3.3 Japan Hepatitis Vaccine Revenue (USD Million) and Forecast By Distribution Channel, 2021-2033
- 10.4 India
- 10.4.1 India Hepatitis Vaccine Revenue (USD Million) and Forecast By Indication, 2021-2033
- 10.4.2 India Hepatitis Vaccine Revenue (USD Million) and Forecast By Vaccine Type, 2021-2033
- 10.4.3 India Hepatitis Vaccine Revenue (USD Million) and Forecast By Distribution Channel, 2021-2033
- 10.5 Australia
- 10.5.1 Australia Hepatitis Vaccine Revenue (USD Million) and Forecast By Indication, 2021-2033
- 10.5.2 Australia Hepatitis Vaccine Revenue (USD Million) and Forecast By Vaccine Type, 2021-2033
- 10.5.3 Australia Hepatitis Vaccine Revenue (USD Million) and Forecast By Distribution Channel, 2021-2033
- 10.6 South Korea
- 10.6.1 South Korea Hepatitis Vaccine Revenue (USD Million) and Forecast By Indication, 2021-2033
- 10.6.2 South Korea Hepatitis Vaccine Revenue (USD Million) and Forecast By Vaccine Type, 2021-2033
- 10.6.3 South Korea Hepatitis Vaccine Revenue (USD Million) and Forecast By Distribution Channel, 2021-2033
- 10.7 Rest of Asia-Pacific
- 10.7.1 Rest of Asia-Pacific Hepatitis Vaccine Revenue (USD Million) and Forecast By Indication, 2021-2033
- 10.7.2 Rest of Asia-Pacific Hepatitis Vaccine Revenue (USD Million) and Forecast By Vaccine Type, 2021-2033
- 10.7.3 Rest of Asia-Pacific Hepatitis Vaccine Revenue (USD Million) and Forecast By Distribution Channel, 2021-2033
- 10.8 Asia Pacific PEST Analysis
- CHAPTER 11 Latin America Hepatitis Vaccine Market By Country
- 11.1 Latin America Hepatitis Vaccine Market Overview
- 11.2 Brazil
- 11.2.1 Brazil Hepatitis Vaccine Revenue (USD Million) and Forecast By Indication, 2021-2033
- 11.2.2 Brazil Hepatitis Vaccine Revenue (USD Million) and Forecast By Vaccine Type, 2021-2033
- 11.2.3 Brazil Hepatitis Vaccine Revenue (USD Million) and Forecast By Distribution Channel, 2021-2033
- 11.3 Mexico
- 11.3.1 Mexico Hepatitis Vaccine Revenue (USD Million) and Forecast By Indication, 2021-2033
- 11.3.2 Mexico Hepatitis Vaccine Revenue (USD Million) and Forecast By Vaccine Type, 2021-2033
- 11.3.3 Mexico Hepatitis Vaccine Revenue (USD Million) and Forecast By Distribution Channel, 2021-2033
- 11.4 Rest of Latin America
- 11.4.1 Rest of Latin America Hepatitis Vaccine Revenue (USD Million) and Forecast By Indication, 2021-2033
- 11.4.2 Rest of Latin America Hepatitis Vaccine Revenue (USD Million) and Forecast By Vaccine Type, 2021-2033
- 11.4.3 Rest of Latin America Hepatitis Vaccine Revenue (USD Million) and Forecast By Distribution Channel, 2021-2033
- 11.5 Latin America PEST Analysis
- CHAPTER 12 Middle East & Africa Hepatitis Vaccine Market By Country
- 12.1 Middle East & Africa Hepatitis Vaccine Market Overview
- 12.2 GCC
- 12.2.1 GCC Hepatitis Vaccine Revenue (USD Million) and Forecast By Indication, 2021-2033
- 12.2.2 GCC Hepatitis Vaccine Revenue (USD Million) and Forecast By Vaccine Type, 2021-2033
- 12.2.3 GCC Hepatitis Vaccine Revenue (USD Million) and Forecast By Distribution Channel, 2021-2033
- 12.3 South Africa
- 12.3.1 South Africa Hepatitis Vaccine Revenue (USD Million) and Forecast By Indication, 2021-2033
- 12.3.2 South Africa Hepatitis Vaccine Revenue (USD Million) and Forecast By Vaccine Type, 2021-2033
- 12.3.3 South Africa Hepatitis Vaccine Revenue (USD Million) and Forecast By Distribution Channel, 2021-2033
- 12.4 Rest of Middle East & Africa
- 12.4.1 Rest of Middle East & Africa Hepatitis Vaccine Revenue (USD Million) and Forecast By Indication, 2021-2033
- 12.4.2 Rest of Middle East & Africa Hepatitis Vaccine Revenue (USD Million) and Forecast By Vaccine Type, 2021-2033
- 12.4.3 Rest of Middle East & Africa Hepatitis Vaccine Revenue (USD Million) and Forecast By Distribution Channel, 2021-2033
- 12.5 Middle East & Africa PEST Analysis
- CHAPTER 13 Player Analysis Of Hepatitis Vaccine Market
- 13.1 Hepatitis Vaccine Market Company Share Analysis
- 13.2 Competition Matrix
- 13.2.1 Competitive Benchmarking of key players by price, presence, market share, and R&D investment
- 13.2.2 New Product Launches and Product Enhancements
- 13.2.3 Mergers And Acquisition In Global Hepatitis Vaccine Market
- 13.2.4 Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
- CHAPTER 14 Company Profile
- 14.1 GSK plc
- 14.1.1 Company Snapshot
- 14.1.2 Business Overview
- 14.1.3 Financial Overview
- 14.1.3.1 Revenue (USD Million), 2024
- 14.1.3.2 GSK plc 2024 Hepatitis Vaccine Business Regional Distribution
- 14.1.4 Product /Service and Specification
- 14.1.5 Recent Developments & Business Strategy
- 14.2 DYNAVAX TECHNOLOGIES
- 14.3 VBI Vaccines Inc.
- 14.4 Sanofi
- 14.5 Merck & Co., Inc.
- 14.6 Takeda Pharmaceutical Company Limited
- 14.7 Sinovac Biotech Ltd.
- 14.8 Biokangtai
- 14.9 Pfizer Inc.
- 14.10 Gilead Sciences, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
